Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared a post on X:
“Fantastic poster AACR25 by our newest Phase 1 clinical trial oncologist, Dr. Deepak Bhamidipati!
His first presentation post-fellowship highlights. The impact of Project Optimus and FDA guidance on early-phase trial design.
Join us in welcoming him to the drug development world.”
Learn more about drug development on OncoDaily.